PNS |
Human granulocytic HL-60, erythrocytic K562, megakaryocytic CHRF-288, and Meg-01 cell line |
Promote proliferation and differentiation |
Kinase MEK-1↑, MEK-2↑, ERK-1↑, ERK-2↑, AKT-1↑, AKT-2↑, PI3K↑ |
Fan et al., 2012
|
PNS |
THP-1 macrophage cells |
Reduced secretion of inflammatory factors |
LXRalpha↑, ABCA1↑, ABCG1↑, NF-κB↓, IL-6↓, MCP-1↓ |
Dou et al., 2012
|
PNS |
Apo-E-deficient mice |
Inhibit the progression of atherosclerotic lesions via antioxidant/anti-inflammatory biological properties |
VCAM-1↓, ICAM-1↓, MCP-1↓, RAGE↓, NF-κB↓, JNK, p38(MAPK)↓, ERK1/2↓ |
Aronoff et al., 2004
|
PNS |
Peritoneal macrophage cells |
Enhanced phagocytosis |
COX-2, PGE↓, PGD↑ |
Yuan et al., 2009
|
PNS |
Haemorrhagic shock rats |
Protective to rat haemorrhagic shock model by antioxidative stress and anti-inflammation |
ICAM-1↓, SOD↑, MDA↓, endotoxin↓, MPO↓, TNF alpha↓, IL-6↓ |
Liu H. Z. et al., 2014
|
NG |
Rat washed platelets |
Inhibit ADP-induced platelet aggregation |
Grb2↑, thrombospondin 1↑, tubulin alpha 6↑, thioredoxin↑, Cu–Zn superoxide dismutase, DJ-1↑, peroxiredoxin 3↑, thioredoxin-like protein 2↑, ribonuclease inhibitor↑, potassium channel subfamily V member 2↑, myosin regulatory light chain 9↑, laminin receptor 1↑ |
Yao et al., 2008a
|
Ginsenoside-Rd |
Basilar artery smooth muscle cells |
Inhibit cell proliferation and reversed basilar artery remodeling |
Cytochrome C↑, caspase-9/caspase-3↑, MMP↓, Bcl-2/Bax↓, Cyclosporine A↓ |
Li et al., 2012
|
NR1 |
Human endothelial EA. hy926 cells |
Suppress oxLDL-induced inflammatory cytokines production |
PPARgamma↑, NF-κB↓, MAPK↓ |
Su et al., 2016
|
NR1 |
Human aortic smooth muscle cells |
Inhibits TNF-alpha-induced PAI-1 production |
ERK↓, PKB↓ |
Zhang and Wang, 2006
|
NR1 |
H9c2 cardiomyocytes |
Reduced cardiomyocyte apoptosis and inflammation |
ERalpha↑ |
Zhong et al., 2015
|
NR1 |
Endotoxaemic mice |
Protection of cardiac function |
ERalpha↑, phospho-Akt↑, phospho-GSK3beta↑, I-κB alpha↑ |
Sun B. et al., 2013
|
Ginsenoside Rg1 |
Hypoxia/reoxygenation cardiomyocytes |
Antioxidative effect |
ROS↓, T-SOD↑, CAT↑, GSH↑ |
Zhu et al., 2009
|
PNS |
Foam cells |
Decrease cholesterol ester |
ABCA1↑ |
Jia et al., 2010
|
PNS |
CAD rats |
Improve lipid metabolism |
LPL↑, FABP4↓, CPT-1A↓, cytochrome P450↑, PPARalpha↓, PPARgamma↓, RXRA↓, PGC-1alpha↓ |
Fan et al., 2012
|
PNS |
Atherosclerosis rats |
Regulate the blood lipid profile and anti-inflammation |
Integrins↓, IL-18↓, IL-1beta↓, MMP-2↓, MMP-9↓, NF-κB/p65↓, IκBalpha↑ |
Zhang et al., 2008
|
PNS |
Atherosclerosis rabbit |
Regulate the blood lipid profile and anti-inflammation |
IL-6↓, CRP↓, MCP-1↓, NF-κB/p65↓ |
Liu et al., 2010
|
PNS |
apoE(−/−) mice |
Prevent the development of atherosclerosis |
Ca2+ influx↑, SR-A↓ |
Hall et al., 2005
|
Ginsenoside-Rd |
Macrophage cells |
Inhibits ox-LDL-induced foam cell formation |
Ca2+ influx↑ |
Hall et al., 2005
|
PNS |
Endothelial cells |
Inhibit platelet activation |
COX-2, 6-keto-PGF1alpha↑, COX-1↓, TXB2↓ |
Wang M. M. et al., 2016
|
PNS |
Rats |
Inhibit ADP-induced platelet aggregation of platelet rich plasma |
|
Yao et al., 2008b
|
PNS |
Rabbit and human platelet |
Anti-platelet aggregation |
ERK2↓, p38↓ |
Qi et al., 2016
|
PNS, ginsenosides (Rg1, Re, and NR1) |
Human plasma |
Anticoagulation activity |
|
Li et al., 2013
|
Ginsenosides, Rg1, Rg2 |
Rat washed platelets |
Enhanced platelet aggregation |
Ca2+↑, P2Y12 receptors↑ |
Gao et al., 2014
|
notoginsenoside Ft1 |
HEK293 cells |
None |
Ca2+↑, P2Y12 receptors↑, cAMP, phosphorylation of PI3K↑, Akt↑ |
Gao et al., 2014
|
NR1 |
Cultured HUVECs |
Activate tissue-type plasminogen |
TPA↑, TPA-PAI-1 complexes↑ |
Zhang et al., 1994
|
PNS |
H9c2 cells |
Anti-apoptosis |
PI3K↑, p-Akt↑ |
Li et al., 2014
|
PNS |
Myocardial ischaemia injury rats |
Improved cardiac function in rats |
p-Akt↑ |
Wang et al., 2015
|
PNS |
Rat aorta after balloon angioplasty |
Inhibit intima hyperplasia by inhibiting VSMCs proliferation |
PCNA↓ |
Wang et al., 2009
|
PNS |
VSMCs |
Inhibit VSMCs proliferation and induce VSMCs apoptosis |
p53↑, Bax↑, caspase-3↑, Bcl-2↓ |
Xu et al., 2011
|
PNS |
VSMCs |
inhibit VSMCs proliferation |
cyclinD1↓, CDK4↓, p21↓, P-ERK1/2↓, MKP-1↑ |
Zhang et al., 2012
|
PNS |
Human umbilical vein endothelial cells(HUVECs) |
Stimulate the proliferation of HUVECs |
PI3K↑, Akt↑, eNOS↑ |
Hong et al., 2009
|
PNS |
Zebrafish |
Promote changes in the subintestinal vessels |
VEGF-KDR/Flk-1↑ |
Hong et al., 2009
|
Notoginsen-oside F1 |
HUVECs |
Pro-angiogenesis, stimulate the proliferation of HUVECs |
VEGF-KDR/Flk-1↑, PI3K↑, eNOS↑, Akt↑ |
Yang et al., 2016
|
Notoginsen-oside F1 |
Rat mesenteric arteries |
Induce endothelium-dependent relaxation |
eNOS↑, ER beta↑, Akt↑, ERK1/2↓ |
Shen et al., 2014
|
PNS |
Apolipoprotein E-knockout mice |
Lower serum lipid levels |
CD40↓, MMP-9↓ |
Liu et al., 2009
|
PNS |
Apolipoprotein E-knockout mice |
Reduce the size of atherosclerotic plaque |
SDF-1 alpha↑, SCF↑, MMP-9↑, CXCR4↑ |
Liu et al., 2013
|
PNS |
Zymosan A induced atherosclerosis rats |
Inhibit atherogenesis |
p-FAK↓, NF-κB↓ |
Zhang et al., 1994
|
PNS |
Acute myocardial ischaemia in anesthetic dogs |
Attenuate the damage of myocardial ischaemia and infarction |
ET↓, TXA2↓, MBF↑ |
Yuan et al., 2011
|
PNS |
Post-myocardial infarction-ventricular rats |
Reduce pathological injury of cardiac myocytes in myocardial ischaemia and cardiac muscle |
ACE2↑, TNF-alpha↓ |
Guo et al., 2010
|
PNS |
Rabbits after balloon endothelial denudation (BED) |
Promote endothelial, regeneration and reduce extracellular matrix thickening |
VEGF↓, MMP-2↓ |
Liu et al., 2009
|
PNS |
Cardiomyocytes with hypoxia-reoxygenation |
Inhibit apoptosis and improve energy metabolism |
|
Gong et al., 2013
|
NG |
Rats of ischaemia-reperfusion (IR) |
Cardioprotective effect |
|
Yue et al., 2012
|
Ginsenoside Rg1, Rb1 |
Myocardial infarction rats |
Improved heart contractility |
|
Deng et al., 2015
|